rofecoxib has been researched along with thromboxane a2 in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| García Rodríguez, LA; Patrignani, P; Patrono, C | 1 |
| Vane, JR | 1 |
| Austin, SC; Cheng, Y; Coffman, TM; FitzGerald, GA; Grosser, T; Koller, BH; Lawson, JA; Rocca, B | 1 |
| Frankish, H | 1 |
| Calhoun, BC; Hoeldtke, NJ; Howard, BC; Kovac, CM; Napolitano, PG | 1 |
| Gately, S; Li, WW | 1 |
| Fitzgerald, GA | 1 |
| Byrne, D; McAdam, BF; Morrow, JD; Oates, JA | 1 |
| de Leon-Casasola, OA; Kotob, F; Lema, MJ | 1 |
| Bishop-Bailey, D; Mitchell, JA; Vojnovic, I; Warner, TD | 1 |
| Guo, ZR | 1 |
| Dogné, JM; Hanson, J; Pratico, D; Supuran, C | 1 |
| Cerletti, C; Dell'Elba, G; Evangelista, V; Manarini, S; Rotondo, S | 1 |
| Marwali, MR; Mehta, JL | 1 |
5 review(s) available for rofecoxib and thromboxane a2
| Article | Year |
|---|---|
Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Blood Platelets; Cardiovascular Diseases; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Depression, Chemical; Dinoprostone; Epoprostenol; Gastric Mucosa; Gastrointestinal Hemorrhage; Humans; Incidence; Intestinal Mucosa; Isoenzymes; Lactones; Membrane Proteins; Peptic Ulcer; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrazoles; Randomized Controlled Trials as Topic; Substrate Specificity; Sulfonamides; Sulfones; Thromboembolism; Thromboxane A2; Treatment Outcome | 2001 |
Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy.
Topics: Angiogenesis Inhibitors; Animals; Anticarcinogenic Agents; Celecoxib; Cell Movement; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Epidermal Growth Factor; Epoprostenol; Humans; Interleukin-12; Isoenzymes; Lactones; Matrix Metalloproteinases; Membrane Proteins; Neoplasms; Neovascularization, Pathologic; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Signal Transduction; Sulfonamides; Sulfones; Thromboxane A2; Vascular Endothelial Growth Factor A | 2004 |
[Innovation of anti-inflammatory drugs--inhibition of cyclooxygenases].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Epoprostenol; Humans; Lactones; Pyrazoles; Sulfonamides; Sulfones; Thromboxane A2 | 2005 |
Coxibs and cardiovascular side-effects: from light to shadow.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Epoprostenol; Humans; Isoxazoles; Lactones; Pyrazoles; Structure-Activity Relationship; Sulfonamides; Sulfones; Thromboxane A2 | 2006 |
COX-2 inhibitors and cardiovascular risk. Inferences based on biology and clinical studies.
Topics: Animals; Blood Platelets; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Labeling; Endothelium, Vascular; Epoprostenol; Humans; Lactones; Platelet Aggregation; Product Surveillance, Postmarketing; Pyrazoles; Randomized Controlled Trials as Topic; Risk Assessment; Sulfonamides; Sulfones; Thromboxane A2 | 2006 |
1 trial(s) available for rofecoxib and thromboxane a2
| Article | Year |
|---|---|
Contribution of cyclooxygenase-2 to elevated biosynthesis of thromboxane A2 and prostacyclin in cigarette smokers.
Topics: Adult; Cross-Over Studies; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Double-Blind Method; Epoprostenol; Humans; Lactones; Male; Membrane Proteins; Platelet Activation; Prostaglandins; Reference Values; Smoking; Sulfones; Thromboxane A2 | 2005 |
8 other study(ies) available for rofecoxib and thromboxane a2
| Article | Year |
|---|---|
Biomedicine. Back to an aspirin a day?
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carotid Artery Injuries; Cell Division; Clinical Trials as Topic; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Epoprostenol; Homeostasis; Humans; Isoenzymes; Lactones; Membrane Proteins; Mice; Muscle, Smooth, Vascular; Myocardial Infarction; Naproxen; Platelet Activation; Prostaglandin-Endoperoxide Synthases; Receptors, Epoprostenol; Receptors, Prostaglandin; Receptors, Thromboxane; Sulfones; Thromboxane A2 | 2002 |
Role of prostacyclin in the cardiovascular response to thromboxane A2.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Carotid Artery Injuries; Carotid Artery, Common; Cell Division; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Endothelium, Vascular; Epoprostenol; Humans; Isoenzymes; Lactones; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Muscle, Smooth, Vascular; Naphthalenes; Platelet Activation; Platelet Aggregation; Propionates; Prostaglandin-Endoperoxide Synthases; Receptors, Epoprostenol; Receptors, Prostaglandin; Receptors, Thromboxane; Sulfones; Tetrahydronaphthalenes; Thromboxane A2; Tunica Intima | 2002 |
Why do COX-2 inhibitors increase risk of cardiovascular events?
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Lactones; Membrane Proteins; Mice; Myocardial Infarction; Naproxen; Prostaglandin-Endoperoxide Synthases; Sulfones; Thromboxane A2 | 2002 |
The effects of a cyclo-oxygenase II inhibitor on placental artery production of thromboxane and prostacyclin.
Topics: Angiotensin II; Arteries; Culture Media; Culture Techniques; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprost; Epoprostenol; Female; Humans; Isoenzymes; Lactones; Membrane Proteins; Placenta; Pregnancy; Prostaglandin-Endoperoxide Synthases; Sulfones; Thromboxane A2 | 2003 |
Coxibs and cardiovascular disease.
Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Approval; Drug Industry; Epoprostenol; Gastrointestinal Diseases; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Naproxen; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Risk; Sulfonamides; Sulfones; Thromboxane A2; United States; United States Food and Drug Administration | 2004 |
NSAIDs and cardiovascular risk.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular System; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Hypertension; Lactones; Sulfones; Thromboxane A2 | 2005 |
Influence of plasma protein on the potencies of inhibitors of cyclooxygenase-1 and -2.
Topics: Aspirin; Blood Platelets; Blood Proteins; Calcimycin; Calcium; Celecoxib; Cell Line; Cerebrospinal Fluid Proteins; Cyclooxygenase 1; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Dinoprostone; Humans; Indomethacin; Ionophores; Lactones; Meloxicam; Naproxen; Organ Specificity; Organic Chemicals; Protein Binding; Pyrazoles; Sodium Salicylate; Sulfonamides; Sulfones; Synovial Fluid; Thiazines; Thiazoles; Thromboxane A2 | 2006 |
The lipoxygenase-cyclooxygenase inhibitor licofelone prevents thromboxane A2-mediated cardiovascular derangement triggered by the inflammatory peptide fMLP in the rabbit.
Topics: Acetates; Animals; Aspirin; Blood Pressure; Cyclooxygenase Inhibitors; Disease Models, Animal; Electrocardiography; Heart Rate; Inflammation; Lactones; Leukotriene B4; Lipoxygenase Inhibitors; Male; Myocardial Ischemia; N-Formylmethionine Leucyl-Phenylalanine; Pyrroles; Rabbits; Sulfones; Thromboxane A2; Time Factors | 2006 |